Terbinafine HCl Tablets are the generic version of Novartis' Lamisil(R) Tablets. Terbinafine HCl Tablets had U.S. sales of approximately $685 million for the 12 months ending March 31, 2007, for the same strength.
This product will be shipped immediately.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit http://www.mylan.com.
